An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study
is designed to enroll subjects who have successfully completed one of the following studies
of IPX066:

- IPX066-B08-05 (A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066
in Subjects with Parkinson's Disease)

- IPX066-B08-11 (A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to
Standard Carbidopa - Levodopa)

- IPX066-B09-02 (A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced
Parkinson's Disease)

All participants will be given IPX066 for 9 months.

Inclusion Criteria:

- Each subject must meet the following inclusion criteria in order to be enrolled in
the study:

1. Successful completion of studies IPX066-B08-05, IPX066-B08-11, or IPX066-B09-02.

2. In the opinion of the Investigator, the Parkinson's disease diagnosis is still
valid and the subject remains eligible for LD therapy.

Exclusion Criteria:

- Each subject must be free of the following exclusion criteria in order to be enrolled
in the study:

1. Received an investigational medication other than those from an IPX066 trial
within 4 weeks prior to the planned start of treatment.

2. Anticipates functional neurosurgical treatment for PD (e.g., ablation or deep
brain stimulation) during study participation.

3. Received within 4 weeks prior to Baseline Visit or planning to take during study
participation: nonselective monoamine oxidase (MAO) inhibitors (with the
exception of rasagiline).

4. In the opinion of the Investigator, should not participate in the study.